Structured lifestyle interventions, including medical nutrition therapy or supervised weight loss programs
Custom support plans to manage lifestyle changes after medication
Two of the most popular GLP-1s on the market today are semaglutide (sold as Ozempic, Wegovy, and Rybelsus) and the latest, tirzepatide (sold as Mounjaro and Zepbound)
UnitedHealthcare typically requires BMI 30 kg/m, or BMI 27 kg/m with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or cardiovascular disease)
Meanwhile, Wegovy and similar medications are structured for chronic weight management, offering differing dosages and clinical support data
Christopher Oseh Christopher Oseh, MD, is a trained primary care physician leveraging almost a decade of clinical experience managing and counseling patients toward better health through positive lifestyle changes